Search Menu
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information
Search Scholarly Publications

Title: Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib

Journal Article · · Journal of Biological Chemistry
; ; ; ; ; ; ; ; ORCiD logo; ORCiD logo

Not Available

Sponsoring Organization:
USDOE
Grant/Contract Number:
NONE; AC02-76SF00515
OSTI ID:
1766585
Journal Information:
Journal of Biological Chemistry, Journal Name: Journal of Biological Chemistry Journal Issue: 27 Vol. 294; ISSN 0021-9258
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
English

References (39)

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial journal January 2017
PRODRG : a tool for high-throughput crystallography of protein–ligand complexes journal July 2004
Novel Targets in Non‐Small Cell Lung Cancer: ROS1 and RET Fusions journal May 2013
Features and development of Coot journal March 2010
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs journal January 2011
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases journal December 2017
REFMAC 5 dictionary: organization of prior chemical knowledge and guidelines for its use journal November 2004
Announcing the worldwide Protein Data Bank journal December 2003
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain journal November 2006
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers journal January 2017
Drug resistance profiles of mutations in the RET kinase domain: Drug sensitivity profiles of RET kinase mutations journal July 2018
MolProbity : all-atom structure validation for macromolecular crystallography journal December 2009
Precision Targeted Therapy with BLU-667 for RET -Driven Cancers journal April 2018
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes journal January 2016
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update journal August 2013
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space journal September 2013
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine journal May 2015
Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions journal November 2004
Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry journal May 2017
Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial journal December 2016
Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors journal February 2007
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients journal September 2016
Thermodynamic Penalty Arising from Burial of a Ligand Polar Group Within a Hydrophobic Pocket of a Protein Receptor journal October 2006
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial journal January 2012
UCSF Chimera?A visualization system for exploratory research and analysis journal January 2004
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer journal June 2014
Selective RET kinase inhibition for patients with RET-altered cancers journal August 2018
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived journal July 2018
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC journal November 2018
Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer journal May 2017
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer journal November 2013
Molecular replacement with MOLREP journal December 2009
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) journal May 2016
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations journal October 2006
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib journal June 2017
A secondary RET mutation in the activation loop conferring resistance to vandetanib journal February 2018
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma journal August 2016
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies journal April 2018

Similar Records

Related Subjects